Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Aleve Sinus & Headache NDA

This article was originally published in The Tan Sheet

Executive Summary

Labeling supplement (NDA 21-076/S7) for naproxen sodium 220 mg/extended-release pseudoephedrine 120 mg combination approved by FDA July 31. Bayer says agency asked it to file formal supplement to add the Sinus & Headache sub-brand under previously approved NDA for Aleve Cold & Sinus; both products contain the same formulation. Sinus & Headache began shipping in July 2001 (1"The Tan Sheet" July 9, 2001, p. 3)...

You may also be interested in...

Bayer Alka-Seltzer Morning Relief Eases Hangover Headaches, Fatigue

Alka-Seltzer Morning Relief will be the first OTC product "specifically indicated to relieve morning headache and fatigue associated with a hangover," Bayer Consumer Care claimed.

China Poised To Conditionally Approve First COVID Vaccine

The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.

Novartis Faces Another Challenge To Entresto In India

More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts